Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing
Authors
Keywords
-
Journal
CANCER GENE THERAPY
Volume 22, Issue 4, Pages 188-197
Publisher
Springer Nature
Online
2015-01-30
DOI
10.1038/cgt.2015.4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Nogo Receptor NgR1 Mediates Infection by Mammalian Reovirus
- (2014) Jennifer L. Konopka-Anstadt et al. Cell Host & Microbe
- Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
- (2014) Kimberly P Kicielinski et al. MOLECULAR THERAPY
- Oncolytic Reovirus in Canine Mast Cell Tumor
- (2013) Chung Chew Hwang et al. PLoS One
- Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
- (2013) J S Carew et al. Cell Death & Disease
- TGF-β Signaling, Activated Stromal Fibroblasts, and Cysteine Cathepsins B and L Drive the Invasive Growth of Human Melanoma Cells
- (2012) Miao Yin et al. AMERICAN JOURNAL OF PATHOLOGY
- Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
- (2012) Katie Twigger et al. BMC CANCER
- Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
- (2012) E. M. Karapanagiotou et al. CLINICAL CANCER RESEARCH
- TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles
- (2012) T. Matsushima-Miyagi et al. CLINICAL CANCER RESEARCH
- Recent Clinical Experience with Oncolytic Viruses
- (2012) O. G. Donnelly et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Reovirus: A Targeted Therapeutic--Progress And Potential
- (2012) R. Maitra et al. MOLECULAR CANCER RESEARCH
- Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma
- (2012) Evanthia Galanis et al. MOLECULAR THERAPY
- Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells
- (2011) Alice Barbarin et al. BIOCHEMICAL JOURNAL
- Apoptosis Induced by Mammalian Reovirus Is Beta Interferon (IFN) Independent and Enhanced by IFN Regulatory Factor 3- and NF- B-Dependent Expression of Noxa
- (2011) J. J. Knowlton et al. JOURNAL OF VIROLOGY
- Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction and augments bortezomib-mediated apoptosis in multiple myeloma
- (2011) K R Kelly et al. ONCOGENE
- Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection
- (2011) Shaun Rosebeck et al. VIROLOGY
- Susceptibility of mantle cell lymphomas to reovirus oncolysis
- (2009) Tommy Alain et al. LEUKEMIA RESEARCH
- Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles
- (2008) W J van Houdt et al. CANCER GENE THERAPY
- Reovirus infection of cancer cells is not due to activated Ras pathway
- (2008) L Song et al. CANCER GENE THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started